TIDMMXCT TIDMTTM
RNS Number : 1251U
MaxCyte, Inc.
21 November 2019
Vor Biopharma and MaxCyte Announce Clinical and Commercial
License Agreement for Engineered Hematopoietic Stem Cells (eHSCs)
to Treat Cancer
- Clinical and commercial agreement using MaxCyte's recently
launched ExPERT(TM) platform enables up to five of Vor's engineered
cell therapies and includes development and approval milestones and
sales-based payments
- Takes MaxCyte's total number of partnered commercial licenses to seven
CAMBRIDGE, Mass. & GAITHERSBURG, Md., (November 21,
2019)-Vor Biopharma, an oncology company pioneering engineered
hematopoietic stem cells (eHSCs) for the treatment of cancer, and
MaxCyte, Inc., (LSE: MXCT, MXCS), a global cell-based therapies and
life sciences company, today announced a clinical and commercial
license agreement under which Vor will use MaxCyte's Flow
Electroporation(R) technology to produce eHSCs and initiate
Investigational New Drug (IND)-enabling studies to accelerate its
progress towards the clinic.
Under the terms of the agreement, Vor obtains non-exclusive
clinical and commercial use rights to MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform to develop up
to five engineered cell therapies, including VOR33, Vor's lead eHSC
candidate, which is in development for acute myeloid leukemia
(AML). In return, MaxCyte will receive undisclosed development and
approval milestones and sales-based payments in addition to other
licensing fees.
Vor will use MaxCyte's cell engineering platform to deliver its
gene editing machinery into hematopoietic stem cells to remove
biologically redundant cell surface proteins that are also
expressed on blood cancer cells. Once the eHSCs are transplanted
into a cancer patient, these cells are effectively hidden from
complementary targeted therapies that target the relevant protein,
while diseased cells are left vulnerable to attack. Vor's approach
thereby could unleash the potential of targeted therapies by
broadening the therapeutic window and improving the utility of
complementary targeted therapies.
"MaxCyte is a leader in GMP electroporation technology, and we
are thrilled that this agreement provides us with long-term access
to a platform technology applicable to a pipeline of eHSC programs
used to treat AML and other blood cancers," said Sadik Kassim,
Ph.D., Chief Technology Officer of Vor. "As we build on promising
in vivo data from our lead candidate VOR33, we can now expand our
manufacturing capabilities to support later-stage studies,
regulatory filings and commercialization of VOR33."
MaxCyte's ExPERT instrument family represents the next
generation of leading, clinically validated, electroporation
technology for complex and scalable cellular engineering. By
delivering high transfection efficiency with enhanced
functionality, the ExPERT platform delivers the high-end
performance essential to enable the next wave of biological and
cellular therapeutics.
"We look forward to expanding our relationship with Vor
Biopharma as the company pioneers a potential future standard of
care in hematopoietic stem cell transplants for cancer patients in
need," said Doug Doerfler, President & CEO of MaxCyte. "This
agreement represents another key business milestone for MaxCyte,
emphasizing the value of our technology platform applied to
next-generation engineered cell therapies that may make a true
difference in patient outcomes."
About VOR33
Vor's lead product candidate, VOR33, consists of engineered
hematopoietic stem cells (eHSCs) that lack the protein CD33. Once
these cells are transplanted into a cancer patient, CD33 becomes a
far more cancer-specific target, potentially avoiding toxicity to
the normal blood and bone marrow associated with CD33-targeted
therapies. In so doing, Vor aims to improve the therapeutic window
and effectiveness of CD33-targeted therapies, thereby potentially
broadening the clinical benefit to patients suffering from AML.
About Vor Biopharma
Vor Biopharma aims to transform the lives of cancer patients by
pioneering engineered hematopoietic stem cell (eHSC) therapies. By
removing biologically redundant proteins from eHSCs, these cells
become inherently invulnerable to complementary targeted therapies
while tumor cells are left susceptible, thereby unleashing the
potential of targeted therapies to benefit cancer patients in
need.
Vor's platform could be used to potentially change the treatment
paradigm of both hematopoietic stem cell transplants and targeted
therapies, such as antibody drug conjugates, bispecific antibodies
and CAR-T cell treatments. A proof-of-concept study for Vor's lead
program has been published in Proceedings of the National Academy
of Sciences.
Vor is based in Cambridge, Mass. and has a broad intellectual
property base, including in-licenses from Columbia University,
where foundational work was conducted by inventor and Vor
Scientific Board Chair Siddhartha Mukherjee, MD, DPhil. Vor was
founded by Dr. Mukherjee and PureTech Health and is supported by
leading investors including 5AM Ventures and RA Capital Management,
Johnson & Johnson Innovation - JJDC, Inc. (JJDC), Novartis
Institutes for BioMedical Research and Osage University
Partners.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use. With its robust delivery
technology platform, MaxCyte helps its partners to unlock the full
potential of their products. For more information, visit
www.maxcyte.com.
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
Vor Media Contact:
Tom Donovan
(857) 559-3397
tom@tenbridgecommunications.com
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
James Stearns +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-com
Chris Welsh
Sukaina Virji
--------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCPGGBCGUPBGMU
(END) Dow Jones Newswires
November 21, 2019 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Maxcyte (LSE:MXCT)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
